Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168332 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3SIRT2SIRT1 | |
| SCHEMBL13394929 | 0.91 | CHRM2 (0.38) | CHRM2CHRM1CHRM3SIRT2SIRT1 | |
| SCHEMBL13394774 | 0.91 | CHRM2 (0.38) | CHRM2CHRM1CHRM3SIRT2SIRT1 | |
| SCHEMBL3173890 | 0.87 | CHRM2 (0.38) | CHRM2CHRM1CHRM3GPR119HDAC1 | |
| SCHEMBL3173882 | 0.87 | CHRM2 (0.38) | CHRM2CHRM1CHRM3GPR119HDAC1 | |
| SCHEMBL3178084 | 0.87 | CHRM2 (0.38) | CHRM2CHRM1CHRM3GPR119HDAC1 | |
| SCHEMBL3173898 | 0.86 | OPRM1 (0.39) | CHRM2CHRM1CHRM3P2RX4OPRM1 | |
| SCHEMBL3167921 | 0.86 | OPRM1 (0.39) | CHRM2CHRM1CHRM3P2RX4OPRM1 | |
| SCHEMBL3167922 | 0.86 | OPRM1 (0.39) | CHRM2CHRM1CHRM3P2RX4OPRM1 | |
| SCHEMBL3168161 | 0.86 | CHRM2 (0.43) | CHRM2CHRM1CHRM3GPR119HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | CHRM2 131/4885CHRM1 98/4885CHRM3 77/4885 |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CHRM2 125/4885CHRM1 93/4885CHRM3 85/4885 |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | OPRD1, OPRK1, OPRL1 | CHRM2 125/4885CHRM1 93/4885CHRM3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.